US Adoptive Cell Therapy Market Size is USD 2.1 Billion in 2025

Market Overview and Definition

The US Adoptive Cell Therapy market size was valued at approximately USD 2.1 billion in 2025 and is projected to reach USD 8.25 billion by 2035, growing at a CAGR of 14.2% during the forecast period.

Adoptive Cell Therapy (ACT) involves the ex vivo expansion and administration of immune cells customized to target specific diseases, notably cancer. The industry ecosystem encompasses biotechnology companies, research institutes, hospitals, and regulatory entities. The therapy is particularly revolutionizing oncology by providing highly personalized treatment solutions, prompting significant investments and strategic partnerships aimed at advancing both autologous and allogeneic therapies.

By Product Type

This segment accounts for approximately 35% of the market. Its significance is driven by breakthroughs in CAR-T cell research and its success in clinical trials. The types include CAR-T Cell Therapy, TIL Therapy, and NK Cell Therapy, each contributing distinct benefits depending on the pathology and patient-specific demands.

Primary Segment Contribution

CAR-T Cell Therapy – 60%: Predominantly used for various cancers due to its high efficacy.

TIL Therapy – 25%: Important for advanced melanoma treatments.

NK Cell Therapy – 15%: Gaining traction for its promise in hematological malignancies.

Table: Product Type Market Share (2025)

By Application

This category contributes 30% of the revenue, deeply rooted in oncology which accounts for the majority market share. As precision medicine evolves, other applications in cardiology and neurology are emerging.

Primary Segment Contribution

Oncology – 70%: Central to the market, with prominent applications in hematologic cancers.

Cardiology – 20%: Emerging application with promising clinical trials for myocardial regeneration.

Neurology – 10%: Pioneering applications in neurodegenerative disease management.

Table: Application Market Share (2025)